If approved, Acadia will sell trofinetide in Europe under license from Neuren. Upon the first commercial sale of the treatment in Europe, Neuren is contracted to receive a US$35 million payment from Acadia. That's in addition to ongoing royalty payments.
How has this led to 10% free fall is beyond me. Smart investors/individuals - please enlighten me here
Ann: Trofinetide marketing application submitted in Europe, page-51
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.24 |
Change
0.385(3.00%) |
Mkt cap ! $1.652B | |||
| Open | High | Low | Value | Volume |
| $13.15 | $13.37 | $12.92 | $4.345M | 331.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 230 | $13.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.24 | 288 | 9 |
View Market Depth
| Last trade - 12.23pm 18/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |